Avapritinib may alleviate skin symptoms in patients with indolent SM long-term
Patients with indolent SM who took avapritinib saw significant improvements in itching, flushing and skin spots that lasted for three years.
Patients with indolent SM who took avapritinib saw significant improvements in itching, flushing and skin spots that lasted for three years.
Individuals with mast cell diseases like SM may experience cardiac, vascular and bleeding symptoms that need specialized care.
Researchers developed an algorithm that helps differentiate SM from hereditary alpha-tryptasemia, a condition with many overlapping symptoms.
KIT D816V mutation testing is simple – all it takes is a blood draw.
This study represents the first known case of a patient with SM with detectable KIT D816V mutations in all cells of the body.
October 20 is International Mastocytosis and Mast Cell Diseases Awareness Day, a day dedicated to showing support and building community.
The case highlights the challenges of diagnosing and treating both KIT-negative SM and SM with an associated hematologic neoplasm (SM-AHN).
Patients who test negative for the KIT D816V mutation may need further testing for clonal mast cell diseases such as SM, a study found.
The WHO guidelines provide a standardized framework that helps doctors provide the right care for patients.
Flow-SuperRCA is a new, ultra-sensitive test to detect the D816V KIT mutation in patients with SM and other mast cell conditions.